Natera Reports Strong Q1 Results, Raises Full-Year Revenue and Gross Margin Guidance

summarizeSummary

Natera reported strong first-quarter 2026 financial results, with revenue surging 38.8% year-over-year, and subsequently raised its full-year 2026 revenue and gross margin guidance.

check_boxKey Events

• Strong Q1 Revenue Growth

  Total revenues for the first quarter of 2026 increased by 38.8% to $696.6 million, up from $501.8 million in Q1 2025.

• Raised Full-Year Guidance

  Natera raised its 2026 annual revenue guidance by $120 million at the midpoint, now projecting $2.74 billion to $2.82 billion, and increased gross margin guidance to 64%-66%.

• Record Test Volumes

  The company processed over one million tests in Q1 2026 for the first time, an 18.5% increase year-over-year, with oncology tests surging 54.4%.

• Positive Cash Inflow

  Natera achieved a positive cash inflow of approximately $11.8 million in the first quarter of 2026, improving its cash position to $1,087.9 million.

auto_awesomeAnalysis

Natera, Inc. delivered robust first-quarter results, significantly exceeding prior-year performance and demonstrating strong operational momentum. The company's decision to raise its full-year 2026 revenue guidance by $120 million at the midpoint, alongside an increase in gross margin guidance, signals management's confidence in continued growth, particularly driven by strong adoption in oncology and women's health. The positive cash inflow for the quarter further strengthens the company's financial position, indicating improved operational efficiency and a solid foundation for future investments in product development and clinical trials.